Mr. Shrenik Ajmera

Shrenik Ajmera brings more than 23 years at the intersection of commercial excellence and healthcare innovation. Beginning with global pharmaceutical leaders Pfizer (Pharmacia) and Bristol Myers Squibb, he navigated the complexities of oncology portfolio launches before turning his focus to patient access. Recognizing the gaps in chronic care, he pioneered India’s first comprehensive medication adherence program, reshaping patient support in the country.

He went on to build an ecosystem of more than 100 disease management programs touching the lives of over 1.2 million patients across chronic and ultra rare conditions. Today he works to solve one of India’s most pressing healthcare challenges, access to unregistered therapies, bridging the gap for patients awaiting critical treatments in oncology, immunology, and rare diseases, so that innovative science translates into tangible hope.

What this experience brings to Gabriel & Co is a deep understanding of how healthcare innovation needs to translate into access and meaningful patient support. His experience across commercial strategy, patient engagement, disease management programmes and access to critical therapies strengthens Gabriel & Co’s ability to look beyond innovation itself and focus on whether the right patients can actually reach and benefit from it.